Valuation: Insmed Incorporated

Market Cap 23.8B 20.8B 19.24B 17.66B 33.42B 2,294B 34B 229B 90.14B 1,120B 89.38B 87.42B 3,867B P/E 2026 *
-43.1x
P/E 2027 * 216x
Enterprise Value 23.24B 20.31B 18.78B 17.24B 32.62B 2,239B 33.19B 224B 88B 1,093B 87.26B 85.34B 3,775B EV / Sales 2026 *
13.7x
EV / Sales 2027 * 8.24x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-2.14%
1 week-9.13%
Current month+0.79%
1 month+12.50%
3 months-24.74%
6 months-33.43%
Current year-38.26%
1 week 105.07
Extreme 105.07
118.94
1 month 94
Extreme 94
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.16
Extreme 20.164
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
7/9/26 Fiscal year

Chief Executive Officer

32,097 0.0148%
7/6/26 Fiscal year

Chief Technology Officer

36,906 0.0170%
6/25/26 Fiscal year

Chief Executive Officer

64,194 0.0296%
Change 5-day change 1-year change 3-year change Capi.($)
-2.14%-9.13%+2.74%+419.13% 23.8B
-3.42%+10.05%+58.59%+87.70% 57.82B
-0.05%-6.20%+55.97%+124.61% 53.71B
-0.47%-1.53%-18.61%-14.60% 23.26B
-0.56%+10.26%+44.03%-3.86% 20.7B
-0.29%-0.08%+38.91%-27.98% 17.81B
-4.55%-8.65%+194.32%+349.58% 16.9B
-2.61%+8.99%+46.11%+691.67% 16.36B
+0.23%-2.49%+24.26%+190.15% 13.96B
-0.86%-2.59%+58.14%+144.60% 12.69B
Average -1.47%+0.68%+50.45%+196.10% 25.7B
Weighted average by Cap. -1.58%+0.04%+49.59%+165.49%

Financials

2026 *2027 *
Net sales 1.7B 1.48B 1.37B 1.26B 2.38B 164B 2.42B 16.37B 6.43B 79.88B 6.38B 6.23B 276B 2.77B 2.42B 2.24B 2.06B 3.89B 267B 3.96B 26.71B 10.49B 130B 10.41B 10.18B 450B
Net income -560M -490M -453M -416M -787M -54B -800M -5.4B -2.12B -26.37B -2.1B -2.06B -91.04B 70.54M 61.66M 57.03M 52.33M 99.04M 6.8B 101M 680M 267M 3.32B 265M 259M 11.46B
Net Debt -566M -494M -457M -419M -794M -54.49B -808M -5.45B -2.14B -26.61B -2.12B -2.08B -91.87B -983M -859M -795M -729M -1.38B -94.73B -1.4B -9.48B -3.72B -46.26B -3.69B -3.61B -160B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-07-16 US$107.46 -2.14% 2,753,863
26-07-15 US$109.81 -0.27% 2,116,813
26-07-14 US$110.11 +0.89% 1,848,330
26-07-13 US$109.14 -5.60% 2,825,240
26-07-10 US$115.61 -2.24% 2,931,618
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
109.81USD
Average target price
196.38USD
Spread / Average Target
+78.84%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock